UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] RSS 2.0 [feed] RSS 1.0 [feed] Atom
Group by: Author | Type
Jump to: A | B | C | D | F | G | H | J | K | L | M | N | O | P | S | T | V | W
Number of items: 137.

A

Al-Azraqi, A; Angus, B; Gokul, S; Sinha, D; Calvert, AH; Lunec, J; (1999) Bcl-2 expression is a potential prognostic co-factor with P53-mutation status in epithelial ovarian carcinoma. British Journal of Cancer , 80 178 - ?.

Al-Azraqi, A; Angus, B; Gokul, S; Sinha, D; Calvert, AH; Lunec, J; (1999) Bcl-2 expression is a potential prognostic co-factor with P53-mutation status in epithelial ovarian carcinoma. BRIT J CANCER , 80 73 - 73.

Al-Mufti, RAM; Pedley, RB; Marshall, D; Begent, RHJ; Hilson, A; Winslet, MC; Hobbs, KEF; (1999) In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines. BRIT J CANCER , 79 (11-12) 1665 - 1671.

Al-Mufti, RAM; Pedley, RB; Marshall, D; Begent, RHJ; Winslet, MCAH; K, EF; (1999) In vitro assessment of lipiodol targeted radiotherapy for primary and metastatic liver cancers. British Journal of Cancer , 79 1665 - 1671.

Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, PJ; Endicott, JA; ... Schultz, R; + view all (1999) In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors. British Journal of Cancer , 80 110 - ?.

B

Batey, MA; Wright, JG; Simmonds, D; Proctor, M; Chapman, F; Fishwick, K; ... Boddy, AV; + view all (1999) Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer. British Journal of Cancer , 80 259 - ?.

Batey, MA; Wright, JG; Simmonds, D; Proctor, M; Chapman, F; Fishwick, K; ... Boddy, AV; + view all (1999) Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer. BRIT J CANCER , 80 93 - 93.

Begent, RHJ; (1999) Targeting cancer therapy. In: BRITISH JOURNAL OF CANCER. (pp. 104 - 109). CHURCHILL LIVINGSTONE

Bentzen, SM; Saunders, MI; Dische, S; (1999) Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiotherapy and Oncology , 53 219 - 226.

Bramwell, VHC; Steward, WP; Nooij, M; Whelan, J; Craft, AW; Grimer, RJ; ... Van Glabbeke, MM; + view all (1999) Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European osteosarcoma intergroup study. J CLIN ONCOL , 17 (10) 3260 - 3269.

Bramwell, VHC; Steward, WP; Nooij, M; Whelan, J; Craft, AW; Grimer, RJ; ... VanGlabbeke, MM; + view all (1999) Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European osteosarcoma intergroup study. Journal Of Clinical Oncology , 17 3260 - 3269.

Bridgewater, JA; Nelstrop, AE; Rustin, GJ; Gore, ME; McGuire, WP; Hoskins, WJ; (1999) Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol , 17 (2) 501 - 508.

Brooks, N; Mchugh, PJ; Lee, M; Hartley, JA; (1999) Repair of DNA damage produced by sequence specific minor groove alkylating agent. PROC AM ASSOC CANCER RES , 40 4118 - 4118.

Brooks, N; McHugh, PJ; Lee, M; Hartley, JA; (1999) The role of base excision repair in the repair of DNA adducts formed by a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size. ANTI-CANCER DRUG DES , 14 (1) 11 - 18.

Burcombe, RJ; Ostler, PJ; Ayoub, AW; Hoskin, PJ; (1999) Staging CT scans in prostate cancer treatment: A retrospective audit. British Journal of Cancer , 80 157 - 157.

C

Calabrese, CR; Thomas, HD; Batey, MA; Boritzki, T; Zhang, K; White, AW; ... Newell, DR; + view all (1999) Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research , 5 543 - ?.

Calvert, AH; Ghokul, S; Al-Azraqi, A; Wright, J; Lind, M; Bailey, N; ... Fenwick, J; + view all (1999) Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. SEMINARS IN ONCOLOGY , 26 (1) 90 - 94.

Calvert, AH; Hughes, AN; Calvert, PM; Plummer, RE; Highley, MS; (1999) MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin. European Journal of Cancer , 35 1146 - ?.

Calvert, AH; Sessa, C; Hughes, A; Jochim, U; Calvert, P; Ghielmini, M; ... Gallant, G; + view all (1999) Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies. European Journal of Cancer , 35 1147 - ?.

Calvert, H; (1999) An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. SEMINARS IN ONCOLOGY , 26 (2) 3 - 10.

Calvert, H; (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl 6) 105 - 108.

Calvert, H; (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl 6) 105 - 108.

Calvert, H; (1999) MTA: Summary and conclusions. SEMIN ONCOL , 26 (2) 105 - 108.

Calvert, PM; Highley, MS; Hughes, AN; Plummer, ER; Azzabi, AST; Verrill, MW; ... Calvert, AH; + view all (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. Clinical Cancer Research , 5 333 - ?.

Calvert, PM; Highley, MS; Hughes, AN; Plummer, ER; Azzabi, AST; Verrill, MW; ... Calvert, AH; + view all (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. CLIN CANCER RES , 5 3796S - 3796S.

Casey, JL; Pedley, RB; King, DJ; Boden, R; Chapman, AP; Yarranton, GT; Begent, RHJ; (1999) Improved tumour targeting of di-Fab ' fragments modified with polyethylene glycol. TUMOR TARGET , 4 (4) 235 - 244.

Casey, JL; Pedley, RB; King, DJ; Green, AJ; Yarranton, GT; Begent, RH; (1999) Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. Br J Cancer , 81 (6) 972 - 980. 10.1038/sj.bjc.6690795.

Casey, JL; Pedley, RB; King, DJ; Green, AJ; Yarranton, GT; Begent, RHJ; (1999) Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. BRIT J CANCER , 81 (6) 972 - 980.

Cassoni, AM; Whelan, JS; (1999) Ewing's sarcoma: hyperfractionated radiotherapy with concurrent chemotherapy: acute toxicity. A prospective single institutional study. In: Sarcoma. (pp. 45 - 45).

Chang, J; Powles, TJ; Allred, DC; Ashey, SE; Clark, GM; Makris, A; ... Dowsett, M; + view all (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. Journal Of Clinical Oncology , 17 3058 - 3063.

Chester, KA; Melton, RG; Hawkins, RR; (1999) Phage technology for producing antibody enzyme fusion proteins. In: Melton, RG and Fox, RJ, (eds.) Enzyme-Prodrug Strategies for Cancer Therapy. Klewer Academic/Plenum Press

Cooke, SP; Pedley, RB; Boden, R; Holliger, P; Winter, G; Begent, RHJ; Chester, KA; (1999) Tumour targeting using MFE-23 :: TNF alpha fusion protein. BRIT J CANCER , 80 85 - 85.

Cooke, SP; Pedley, RB; Boden, R; Holliger, P; Winter, G; Begent, RHJ; Chester, KA; (1999) Tumour targeting using MFE-23::TNF alpha fusion protein. British Journal of Cancer , 80 228 - 228.

Cooke, SP; Pedley, RBB; R, H; P, W; G, B; R H J and Chester, KA; (1999) Tumour targeting using MFE::TNF fusion protein. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 85 - ?).

Cooooke, SP; Pedley, RB; Boden, R; Holliger, P; Winter, G; Begent, RHJ; Chester, KA; (1999) Tumour targeting using MFE-23::TNF alpha fusion protein. In: (Proceedings) British Journal of Cancer. (pp. 228 - 228).

Cummins, D; Hoskin, P; Young, J; Goodman, IL; Coupe, MO; Halil, O; Foy, CJ; (1999) Is a man's facial appearance predictive of how he will die? International Journal of Clinical Practice , 53 140 - 141.

Curtin, NJ; Bowman, KJ; Turner, RN; Huang, B; Loughlin, PJ; Calvert, AH; ... Newell, DR; + view all (1999) Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha(1)-acid glycoprotein binding. BRIT J CANCER , 80 (11) 1738 - 1746.

Curtin, NJ; Kyle, S; Wang, LZ; Durkacz, BW; White, AJ; Srinivasan, S; ... Hostomsky, Z; + view all (1999) Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. Clinical Cancer Research , 5 520 - ?.

Curtin, NJ; Kyle, S; Wang, LZ; Durkacz, BW; White, AJ; Srinivasan, S; ... Hostomsky, Z; + view all (1999) Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. CLIN CANCER RES , 5 3834S - 3834S.

D

De Silva, IU; Clingen, PH; McHugh, PJ; Tilby, MJ; Gregson, SJ; Howard, P; ... Hartley, JA; + view all (1999) The role of nucleotide excision repair in the repair of DNA damage induced by mono- and bifunctional, major and minor groove alkylating agents. BRIT J CANCER , 80 42 - 42.

Deighton, A; Winfield, EA; Venables, K; Aird, EGA; Hoskin, PJ; (1999) Variation in dose distribution for breast radiotherapy: A trial based quality assurance programme in the UK. European Journal of Cancer , 35 342 - 342.

Delaney, CA; Wang, LZ; Kyle, LZ; Srinivasan, S; White, AW; Curtin, NJ; ... Newell, DR; + view all (1999) Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. British Journal of Cancer , 80 62 - ?.

Delaney, CA; Wang, LZ; Kyle, LZ; Srinivasan, S; White, AW; Curtin, NJ; ... Newell, DR; + view all (1999) Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. BRIT J CANCER , 80 44 - 44.

DeSilva, IU; Clingen, PH; Mchugh, PJ; Tilby, MJ; Gregson, SJ; Howard, P; ... Hartley, JA; + view all (1999) The role of nucleotide excision repair in the repair of DNA damage induced by mono- and bifunctional, major and minor groove alkylating agents. British Journal of Cancer , 80 55 - 55.

Dische, S; Saunders, MI; (1999) The CHART regimen and morbidity [Full text available, price (Pounds)16.45]. Acta Oncologica , 38 147 - 152.

Dische, S; Saunders, MI; Sealy, R; Werner, ID; Verma, N; Foy, C; Bentzen, SM; (1999) Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. Radiotherapy and Oncology , 53 93 - 98.

Dowsett, M; Smith, IE; Powles, TJ; Salter, J; Ellis, PM; Johnston, SRD; ... Assersohn, L; + view all (1999) Biological studies in primary medical therapy of breast cancer: The Royal Marsden Hospital experience. In: Howell, A and Dowsett, M, (eds.) ESO Scientific Updates. (113 - 125). Elsevier Science

F

Flynn, AA; Green, AJ; Boxer, G; Pedley, RB; Begent, RH; (1999) A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. Phys Med Biol , 44 (7) N151 - N159.

Flynn, AA; Green, AJ; Boxer, G; Pedley, RB; Begent, RHJ; (1999) A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. PHYS MED BIOL , 44 (7) N151 - N159.

Flynn, AA; Green, AJ; Boxer, GM; Casey, JL; Pedley, RB; Begent, RHJ; (1999) A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. INT J RADIAT ONCOL , 43 (1) 183 - 189.

Frohlich, B; Paulussen, M; Craft, A; Judson, I; Ladenstein, R; Oberlin, O; ... Jurgens, HFEICESS92UE-E99; + view all (1999) Therapiekonzepte bei non-responden/rezidivpatienten mit Eing Sarkomen im kindesalter. In: Annual Meeting of German and Austrian Socities of Haematology and Oncology, October 3-6th 1999. Onkologie Supp II vol 22.

G

Gander, M; Hartley, JM; Spanswick, VJ; Webley, SD; Hochhauser, D; Hartley, JA; (1999) Measurment of DNA interstrand crosslinking in clinical samples using the single cell gel electrophoresis. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH , 40 3410 - 3410.

Ghazal-Aswad, S; Tilby, MJ; Lind, M; Baily, N; Sinha, DP; Calvert, AH; Newell, DR; (1999) Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels. ANN ONCOL , 10 (3) 329 - 334.

GlynneJones, R; Saunders, MI; Hoskin, P; Phillips, H; (1999) A pilot study of continuous, hyperfractionated, accelerated radiotherapy in rectal adenocarcinoma. Clinical Oncology , 11 334 - 339.

Goodchild, K; Hoskin, P; Dische, S; Pigott, K; Powell, M; Saunders, M; (1999) A feasibility study of continuous hyperfractionated accelerated radiotherapy (CHART) and brachytherapy in patients with early oral or oropharyngeal carcinomas. Radiotherapy and Oncology , 50 29 - 31.

Goodchild, KA; Hill, SA; Hoskin, PJ; Saunders, MI; Chaplin, DJ; (1999) Low dose nicotinamide and carbogen improve human tumour blood flow. British Journal of Cancer , 80 244 - 244.

Gorodetsky, R; Lotan, C; Piggot, K; Pierce, LJ; Polyansky, I; Dische, S; ... Vexler, A; + view all (1999) Late effects of dose fractionation on the mechanical properties of breast skin following post-lumpectomy radiotherapy. International Journal of Radiation Oncology Biology Physics , 45 893 - 900.

Griffin, RJ; Barlow, HC; Curtin, NJ; Calvert, AH; Golding, BT; Newell, DR; Smith, PG; (1999) 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). Clinical Cancer Research , 5 564 - ?.

Griffin, RJ; Barlow, HC; Curtin, NJ; Calvert, AH; Golding, BT; Newell, DR; Smith, PG; (1999) 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). CLIN CANCER RES , 5 3843S - 3843S.

Grimaldi, KA; Bingham, JP; Hartley, JA; (1999) PCR-based assays for strand-specific measurement of DNA damage and repair. I. Strand-specific quantitative PCR. Methods Mol Biol , 113 227 - 240. 10.1385/1-59259-675-4:227.

Grimaldi, KA; Bingham, JP; Hartley, JA; (1999) PCR-Based Assys for Strand-Specific Measurement of DNA Damage and Repair I. In: Henderson, DS, (ed.) Methods in Molecular Biology. (227 - 241). Humana Press Inc

Grimaldi, KA; Mac Adam, SR; Hartley, JA; (1999) PCR-Based Assys for Strand-Specific Measurement of DNA Damage and Repair II. In: Henderson, DS, (ed.) Methods in Molecular Biology. (241 - 255). Humana Press

Grimaldi, KA; McAdam, SR; Hartley, JA; (1999) PCR-based assays for strand-specific measurement of DNA damage and repair. II. Single-strand ligation-PCR. Methods Mol Biol , 113 241 - 255. 10.1385/1-59259-675-4:241.

H

Hargreaves, RHJ; O'Hare, CC; Hartley, JA; Ross, D; Butler, J; (1999) Cross-linking and sequence-specific alkylation of DNA by aziridinylquinones. 3. Effects of alkyl substituents. J MED CHEM , 42 (12) 2245 - 2250.

Hartley, JA; O'Hare, CC; Baumgart, J; (1999) DNA alkylation and interstrand cross-linking by treosulfan. BRIT J CANCER , 79 (2) 264 - 266.

Hartley, JM; Spanswick, VJ; Gander, M; Giacomini, G; Whelan, J; Souhami, RL; Hartley, JA; (1999) Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. CLIN CANCER RES , 5 (3) 507 - 512.

Hochhauser, D; (1999) Cancer researchers get down to arrays at AACR. LANCET , 353 (9162) 1418 - 1418.

Hochhauser, D; Valkov, NI; Gump, JL; Wei, I; O'Hare, C; Hartley, J; ... Sullivan, DM; + view all (1999) Effects of wild-type p53 expression on the quantity and activity of topoisomerase II alpha and beta in various human cancer cell lines. J CELL BIOCHEM , 75 (2) 245 - 257.

Hoskin, PJ; Abdelath, O; Phillips, H; Gilligan, S; Saunders, MI; Broderick, P; Baddeley, H; (1999) Inspired and expired gas concentrations in man during carbogen breathing. Radiotherapy and Oncology , 51 175 - 177.

Hoskin, PJ; Saunders, MI; Abdellati, O; Broderick, P; (1999) Capnometry and blood gas measurements in man during carbogen breathing. British Journal of Cancer , 80 328 - 328.

Hoskin, PJ; Saunders, MI; Dische, S; (1999) Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma - Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer , 86 1322 - 1328.

Hoskin, PJ; Saunders, MI; Goodchild, K; Powell, MEB; Taylor, NJ; Baddeley, H; (1999) Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. British Journal of Radiology , 72 1093 - 1098.

Hoskin, PJ; Stratford, M; Folkes, L; Phillips, H; Jackson, S; Regan, J; Yarnold, JR; (1999) Bone markers in response to local radiotherapy for bone pain. British Journal of Cancer , 80 28 - 28.

Hughes, A; Calvert, H; (1999) An update on thymidylate synthase inhibitors. ANN ONCOL , 10 (10) 1137 - 1139.

Hughes, AN; Rafi, I; Griffin, MJ; Calvert, AH; Newell, DR; Calvete, JA; ... Boddy, AV; + view all (1999) Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. CLIN CANCER RES , 5 (1) 111 - 118.

Hunalov, A; Robson, L; Perkins, SJ; Begent, RHJ; Chester, KA; (1999) A vector for expression of dimeric and chelating forms of anti-CEA scFvS. British Journal of Cancer , 80 92 - 92.

Hunalov, A; Robson, L; Perkins, SJ; Begent, RHJ; Chester, KA; (1999) A vector for expression of dimeric and chelating forms of anti-CEA scFvS. BRIT J CANCER , 80 51 - 51.

J

Joiner, MC; Marples, B; Lambin, P; Short, S; Turesson, I; (1999) Low-dose hypersensitivity: current status and possible mechanisms. International Journal of Radiation Oncology Biology Physics , 49 (2) 379 - 389.

K

Kiani-Alikhan, S; Chester, KA; Ledermann, JA; Beverley, PCL; (1999) Potentiation of the activity of dendritic cells by DNA. In: British Journal of Cancer. (pp. 93 - 93).

Kiani-Alikhan, S; Chester, KA; Ledermann, JA; Beverley, PCL; (1999) Potentiation of the activity of dendritic cells by DNA. BRIT J CANCER , 80 52 - 52.

Koberle, B; Masters, JRW; Hartley, JA; Wood, RD; (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. CURR BIOL , 9 (5) 273 - 276.

L

Lee, SM; Radford, JA; Ryder, WD; Deakin, DP; Morgenstern, OR; Scarffe, JH; Crowther, D; (1999) Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. Bone Marrow Transplantation , 24 (3) 271 - 277.

Leevers, SJ; Vanhaesebroeck, B; Waterfield, MD; (1999) Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol , 11 (2) 219 - 225.

M

Maini, MK; Casorati, G; Dellabona, P; Wack, A; Beverley, PCL; (1999) T-cell clonality in immune responses. IMMUNOL TODAY , 20 (6) 262 - 266.

Maini, MK; Soares, MVD; Zilch, CF; Akbar, AN; Beverley, PCL; (1999) Virus-induced CD8(+) T cell clonal expansion is associated with telomerase up-regulation and telomere length preservation: A mechanism for rescue from replicative senescence. J IMMUNOL , 162 (8) 4521 - 4526.

Makris, A; Powles, TJ; Allred, DC; Ashley, SE; Trott, PA; Ormerod, MG; ... Dowsett, M; + view all (1999) Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Research And Treatment , 53 51 - 59.

Makris, A; Powles, TJ; Kakolyris, S; Dowsett, M; Ashley, SE; Harris, AL; (1999) Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer , 85 1996 - 2000.

Mayer, A; Chester, KA; Flynn, AA; Begent, RH; (1999) Taking engineered anti-CEA antibodies to the clinic. J Immunol Methods , 231 (1-2) 261 - 273.

Mayer, A; Chester, KA; Flynn, AA; Begent, RHJ; (1999) Taking engineered anti-CEA antibodies to the clinic. J IMMUNOL METHODS , 231 (1-2) 261 - 273.

McHugh, PJ; Gill, RD; Waters, R; Hartley, JA; (1999) Excision repair of nitrogen mustard-DNA adducts in Saccharomyces cerevisiae. NUCLEIC ACIDS RES , 27 (16) 3259 - 3266. Gold open access

Mchugh, PJ; Hartley, JA; (1999) The induction and repair of DNA doublestrand breaks in nitrogen mustard treated Saccharomyces cerevisiae cells. British Journal of Cancer , 80 54 - 54.

McHugh, PJ; Hartley, JA; (1999) The induction and repair of DNA doublestrand breaks in nitrogen mustard treated Saccharomyces cerevisiae cells. BRIT J CANCER , 80 42 - 42.

N

Napier, MP; Hoare, D; Whelan, JS; (1999) Safe administration of high dose methotrexate in osteosarcoma: Carboxypeptidase G2 for idiosynchratic toxicity. British Journal of Cancer , 80 155 - 155.

Napier, NP; Hoare, D; Whelan, JS; (1999) Safe administration of high dose methotrexate in osteosarcoma: carboxypeptidase G2 for idiosyncratic toxicity. In: British Cancer Research Meeting 1999, Edinburgh.

Neidle, S; Mann, J; Rayner, EL; Baron, A; Opoku-Boahen, Y; Simpson, IJ; ... Kelland, LR; + view all (1999) Symmetric bis-benzimidazoles: new sequence-selective DNA-binding molecules. CHEM COMMUN (10) 929 - 930.

Newby, JC; Leonard, P; Fenwick, E; Harland, SJ; (1999) A phase II study of epirubicin, carboplatin and infusional 5-FU in hormone resistant prostate cancer. British Journal of Cancer , 80 158 - 158.

Newell, DR; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, P; ... Schultz, R; + view all (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Clinical Cancer Research , 5 124 - ?.

Newell, DR; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, P; ... Schultz, R; + view all (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. CLIN CANCER RES , 5 3755S - 3755S.

Nutting, C; Brada, M; Brazil, L; Sibtain, A; Saran, F; Westbury, C; ... Ashley, S; + view all (1999) Radiotherapy in the treatment of benign meningioma of the skull base. J Neurosurg , 90 (5) 823 - 827. 10.3171/jns.1999.90.5.0823.

O

Osborne, M; GlynneJones, R; Galbraith, S; Burcombe, R; Makris, A; (1999) Squamous cell carcinoma antigen as a marker of epidermoid carcinoma of the anal canal. British Journal of Cancer , 80 117 - 117.

Osborne, M; GlynneJones, R; Hoskin, P; Saunders, M; Makris, A; (1999) Continuous hyperfractionated accelerated radiotherapy +/-concurrent infusional 5FU in advanced rectal cancer. British Journal of Cancer , 80 114 - 114.

Osbourn, JK; McCafferty, J; Derbyshire, EJ; Waibel, R; Chester, K; Boxer, G; Allen, D; (1999) Isolation of a panel of human anti-CEA single chain Fv from a large phage display library. Tumor Targeting , 4 150 - 157.

P

Paniwnyk, Z; Pors, K; TeesdaleSpittle, PH; Potter, GA; Plumb, J; Hartley, JA; Patterson, LH; (1999) Novel inhibitor of topo II is effective against resistant ovarian cancer cells. British Journal of Cancer , 80 69 - 69.

Parkinsoin, MC; Harland, SJ; (1999) Testis cancer. In: Mundy, AR and Fitzpatrick, JM and Neal, DE and George, NJR, (eds.) Scientific Basis of Urology. (375 - 394). Isis Medical Media Ltd: Oxford, UK.

Pedley, RB; Sharma, SK; Boxer, GM; Boden, R; Stribbling, SM; Davies, L; ... Begent, RH; + view all (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res , 59 (16) 3998 - 4003.

Pedley, RB; Sharma, SK; Boxer, GM; Boden, R; Stribbling, SM; Davies, L; ... Begent, RHJ; + view all (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. CANCER RES , 59 (16) 3998 - 4003.

Plummer, R; Rees, C; Judson, I; Calvert, H; Highley, M; Trigo, J; ... Smith, M; + view all (1999) Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks. EUR J CANCER , 35 S285 - S285.

Powell, MEB; Collingridge, DR; Saunders, MI; Hoskin, PJ; Hill, SA; Chaplin, DJ; (1999) Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiotherapy and Oncology , 50 167 - 171.

S

Saunders, M; Dische, S; Barrett, A; Harvey, A; Griffiths, G; Parmar, M; (1999) Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. Radiotherapy and Oncology , 52 (2) 137 - 148.

Saunders, MI; Dische, S; Rojas, A; (1999) CHART (continuous, hyperfractionated, accelerated radiotherapy): a tale of two disciplines. British Journal of Cancer , 80 110 - 115.

Shamash, J; Lee, SM; Deakin, DP; Scarffe, JH; Morgenstern, GR; Chang, J; ... Lister, TA; + view all (1999) High dose chemotherapy (HDCT) with autologous haematopoietic support in recurrent or refractory Hodgkin’s lymphoma (HL). In: (Proceedings) British Cancer Research Meeting, Edinburgh.. (pp. 18 - ?). British Journal of Cancer

Shanker, A; Renaut, AJ; Whelan, JS; Taylor, I; (1999) Colorectal cancer in adolescents. Annals of the Royal College of Surgeons of England , 81 (2) 100 - 104.

Short, S; (1999) UNSPECIFIED In: (Proceedings) The Royal College of Radiologists Annual Scientific Meeting.

Short, S; (1999) The response of human glioma cells to low dose radiation. International journal of radiation biology , 75 1341 - 1348.

Short, S; Mayes, C; Woodcock, M; Joiner, MC; (1999) Low-dose hypersensitivity in the T98G glioblastoma cell line. International journal of radiation biology , 75 847 - 855.

Sirotnak, FM; Tolner, B; (1999) Carrier-mediated membrane transport of folates in mammalian cells. ANNU REV NUTR , 19 91 - 122.

Smith, PG; Barlow, HC; Loughlin, P; Huang, B; Bowman, KJ; Calvert, AH; ... Newell, DR; + view all (1999) Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein. British Journal of Cancer , 80 82 - ?.

Smith, PG; Bewley, J; Gogel, JA; Calvert, AH; Newell, DR; Curtin, NJ; Chen, VJ; (1999) MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines. British Journal of Cancer , 80 83 - ?.

Smith, PG; Marshman, E; Calvert, AH; Newell, DR; Curtin, NJ; (1999) Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. SEMINARS IN ONCOLOGY , 26 (2) 63 - 67.

Spanswick, VJ; Hartley, JM; Ward, TH; Hartley, JA; (1999) Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay. Methods Mol Med , 28 143 - 154. 10.1385/1-59259-687-8:143.

Spencer, DIR; Robson, L; Bhatia, J; Sharma, SK; Michael, NP; Whitelegg, NR; ... Begent, RHJ; + view all (1999) Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS. In: BRITISH JOURNAL OF CANCER. (pp. 94 - 94).

Spencer, DIR; Robson, L; Bhatia, J; Sharma, SK; Michael, NP; Whitelegg, NR; ... Bergent, RHJ; + view all (1999) Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS. BRIT J CANCER , 80 52 - 52.

Strauss, S; McTiernan, A; Whelan, JS; (1999) Recurrence of osteosarcoma after disease-free intervals exceeding 5 years. In: British Orthopaedic Oncology Society, March 1999.

Summers, Y; Middleton, MR; Calvert, H; Lee, SM; Rustin, R; Newell, DR; Thatcher, N; (1999) Effect of temozolomide (TMZ) on central nervous system relapse in patients with advanced melanoma. In: (Proceedings) 1999 ASCO Annual Meeting/35th Annual Meeting, Atlanta, GA.. (pp. 531a - ?). Proceedings of the American Society of Clinical Oncology

T

Tolner, B; Singh, A; Esaki, T; Roy, K; Sirotnak, FM; (1999) Transcription of the mouse RFC-1 gene encoding a folate transporter. Multiplicity and properties of promoters with minimum requirements for their basal activity. GENE , 231 (1-2) 163 - 172.

V

Vanhaesebroeck, B; Higashi, K; Raven, C; Welham, M; Anderson, S; Brennan, P; ... Waterfield, MD; + view all (1999) Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. The EMBO Journal , 18 (5) 1292 - 1302.

Vanhaesebroeck, B; Higashi, K; Raven, C; Welham, M; Anderson, S; Brennan, P; ... Waterfield, MD; + view all (1999) Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. EMBO J , 18 (5) 1292 - 1302. 10.1093/emboj/18.5.1292.

Vanhaesebroeck, B; Jones, GE; Allen, WE; Zicha, D; Hooshmand-Rad, R; Sawyer, C; ... Ridley, AJ; + view all (1999) Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat Cell Biol , 1 (1) 69 - 71. 10.1038/9045.

Vanhaesebroeck, B; Waterfield, MD; (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res , 253 (1) 239 - 254. 10.1006/excr.1999.4701.

W

Webley, SD; Francis, R; Begent, RHJ; Hartley, JA; Hochhauser, D; (1999) Measurement of the critical DNA lesions produced by antibody directed enzyme prodrug therapy (ADEPT). BRIT J CANCER , 80 47 - 47.

Wedderburn, LR; Maini, MK; Patel, A; Beverley, PCL; Woo, P; (1999) Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. INT IMMUNOL , 11 (4) 535 - 543.

Whelan, J; Hoare, D; Leonard, P; (1999) Omeprazole does not alter plasma methotrexate clearance. Cancer Chemotherapy and Pharmacology , 44 (1) 88 - 89. 10.1007/s002800050949.

Whelan, JS; Goodchild, K; Strauss, S; McTiernan, A; Driver, D; Kilby, AM; Cassoni, AM; (1999) Intensive induction therapy (VIDE) including stem cell collection for Ewing's family of tumours. In: British Cancer Research Meeting 1999, Edinburgh.

Wilson, SC; Howard, PW; Forrow, SM; Hartley, JA; Adams, LJ; Jenkins, TC; ... Thurston, DE; + view all (1999) Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2,1-c][1,4]benzodiazepine system. J MED CHEM , 42 (20) 4028 - 4041.

Woll, P; Judson, I; Lee, SM; Rodenhuis, S; Nielsen, OS; Buesa, JM; ... Verweij, J; + view all (1999) Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma group. European Journal of Cancer , 35 (3) 410 - 412.

Woll, PJ; Carmichael, J; Chan, S; Howell, A; Ranson, M; Miles, D; ... Welbank, H; + view all (1999) Phase II study results on safety and efficacy of CAELYX (R) (DOXIL (R)) in combination with paclitaxel in the treatment of metastatic breast cancer. EUR J CANCER , 35 S322 - S322.

Wong, KCK; Meyer, T; Harding, DI; Dick, JRT; Vrbova, G; Greensmith, L; (1999) Integrins at the neuromuscular junction are important for motoneuron survival. EUR J NEUROSCI , 11 (9) 3287 - 3292.

This list was generated on Sun Sep 28 03:46:24 2014 BST.